463 related articles for article (PubMed ID: 28972011)
21. APDS patients with immune-complex vasculitis and resolution with leniolisib.
Doroudchi MA; Stephens AV; Wang Z; Dhami J; Butte MJ
Clin Immunol; 2024 May; 262():110176. PubMed ID: 38462154
[TBL] [Abstract][Full Text] [Related]
22. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
[TBL] [Abstract][Full Text] [Related]
23. Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.
Diaz N; Juarez M; Cancrini C; Heeg M; Soler-Palacín P; Payne A; Johnston GI; Helmer E; Cain D; Mann J; Yuill D; Conti F; Di Cesare S; Ehl S; Garcia-Prat M; Maccari ME; Martín-Nalda A; Martínez-Gallo M; Moshous D; Santilli V; Semeraro M; Simonetti A; Suarez F; Cavazzana M; Kracker S
J Immunol; 2020 Dec; 205(11):2979-2987. PubMed ID: 33115853
[TBL] [Abstract][Full Text] [Related]
24. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
Elkaim E; Neven B; Bruneau J; Mitsui-Sekinaka K; Stanislas A; Heurtier L; Lucas CL; Matthews H; Deau MC; Sharapova S; Curtis J; Reichenbach J; Glastre C; Parry DA; Arumugakani G; McDermott E; Kilic SS; Yamashita M; Moshous D; Lamrini H; Otremba B; Gennery A; Coulter T; Quinti I; Stephan JL; Lougaris V; Brodszki N; Barlogis V; Asano T; Galicier L; Boutboul D; Nonoyama S; Cant A; Imai K; Picard C; Nejentsev S; Molina TJ; Lenardo M; Savic S; Cavazzana M; Fischer A; Durandy A; Kracker S
J Allergy Clin Immunol; 2016 Jul; 138(1):210-218.e9. PubMed ID: 27221134
[TBL] [Abstract][Full Text] [Related]
25. Early diagnosis of PI3Kδ syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
Saettini F; Pelagatti MA; Sala D; Moratto D; Giliani S; Badolato R; Biondi A
Immunol Lett; 2017 Oct; 190():279-281. PubMed ID: 28842185
[TBL] [Abstract][Full Text] [Related]
26. Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature.
Olbrich P; Lorenz M; Cura Daball P; Lucena JM; Rensing-Ehl A; Sanchez B; Führer M; Camacho-Lovillo M; Melon M; Schwarz K; Neth O; Speckmann C
Pediatr Allergy Immunol; 2016 Sep; 27(6):640-4. PubMed ID: 27116393
[TBL] [Abstract][Full Text] [Related]
27. Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes.
Redenbaugh V; Coulter T
Front Pediatr; 2021; 9():702872. PubMed ID: 34422726
[TBL] [Abstract][Full Text] [Related]
28. PI3K Orchestrates T Follicular Helper Cell Differentiation in a Context Dependent Manner: Implications for Autoimmunity.
Preite S; Huang B; Cannons JL; McGavern DB; Schwartzberg PL
Front Immunol; 2018; 9():3079. PubMed ID: 30666254
[TBL] [Abstract][Full Text] [Related]
29. PI3K pathway defects leading to immunodeficiency and immune dysregulation.
Nunes-Santos CJ; Uzel G; Rosenzweig SD
J Allergy Clin Immunol; 2019 May; 143(5):1676-1687. PubMed ID: 31060715
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome.
Del Pino-Molina L; Torres Canizales JM; Rodríguez-Pena R; López-Granados E
Cytometry B Clin Cytom; 2021 Jul; 100(4):460-466. PubMed ID: 32961022
[TBL] [Abstract][Full Text] [Related]
31. PI3Kδ and primary immunodeficiencies.
Lucas CL; Chandra A; Nejentsev S; Condliffe AM; Okkenhaug K
Nat Rev Immunol; 2016 Nov; 16(11):702-714. PubMed ID: 27616589
[TBL] [Abstract][Full Text] [Related]
32. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage.
Angulo I; Vadas O; Garçon F; Banham-Hall E; Plagnol V; Leahy TR; Baxendale H; Coulter T; Curtis J; Wu C; Blake-Palmer K; Perisic O; Smyth D; Maes M; Fiddler C; Juss J; Cilliers D; Markelj G; Chandra A; Farmer G; Kielkowska A; Clark J; Kracker S; Debré M; Picard C; Pellier I; Jabado N; Morris JA; Barcenas-Morales G; Fischer A; Stephens L; Hawkins P; Barrett JC; Abinun M; Clatworthy M; Durandy A; Doffinger R; Chilvers ER; Cant AJ; Kumararatne D; Okkenhaug K; Williams RL; Condliffe A; Nejentsev S
Science; 2013 Nov; 342(6160):866-71. PubMed ID: 24136356
[TBL] [Abstract][Full Text] [Related]
33. Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: Case report and literature review.
Yang X; Xi R; Bai J; Pan Y
Medicine (Baltimore); 2023 Feb; 102(5):e32816. PubMed ID: 36749229
[TBL] [Abstract][Full Text] [Related]
34. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency.
Carpier JM; Lucas CL
Front Immunol; 2017; 8():2005. PubMed ID: 29387064
[TBL] [Abstract][Full Text] [Related]
36. CD57 identifies T cells with functional senescence before terminal differentiation and relative telomere shortening in patients with activated PI3 kinase delta syndrome.
Cura Daball P; Ventura Ferreira MS; Ammann S; Klemann C; Lorenz MR; Warthorst U; Leahy TR; Conlon N; Roche J; Soler-Palacín P; Garcia-Prat M; Fuchs I; Fuchs S; Beier F; Brümmendorf TH; Speckmann C; Olbrich P; Neth O; Schwarz K; Ehl S; Rensing-Ehl A
Immunol Cell Biol; 2018 Nov; 96(10):1060-1071. PubMed ID: 29790605
[TBL] [Abstract][Full Text] [Related]
37. Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase δ Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.
Karanovic D; Michelow IC; Hayward AR; DeRavin SS; Delmonte OM; Grigg ME; Dobbs AK; Niemela JE; Stoddard J; Alhinai Z; Rybak N; Hernandez N; Pittaluga S; Rosenzweig SD; Uzel G; Notarangelo LD
Front Immunol; 2019; 10():77. PubMed ID: 30891027
[TBL] [Abstract][Full Text] [Related]
38. Activated phosphoinositde 3-kinase (PI3Kδ) syndrome: an Italian point of view on diagnosis and new advances in treatment.
Lougaris V; Piane FL; Cancrini C; Conti F; Tommasini A; Badolato R; Trizzino A; Zecca M; De Rosa A; Barzaghi F; Pignata C
Ital J Pediatr; 2024 May; 50(1):103. PubMed ID: 38769568
[TBL] [Abstract][Full Text] [Related]
39. Dose-Dependent Suppression of Cytokine production from T cells by a Novel Phosphoinositide 3-Kinase Delta Inhibitor.
Way EE; Trevejo-Nunez G; Kane LP; Steiner BH; Puri KD; Kolls JK; Chen K
Sci Rep; 2016 Jul; 6():30384. PubMed ID: 27461849
[TBL] [Abstract][Full Text] [Related]
40. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency.
Elgizouli M; Lowe DM; Speckmann C; Schubert D; Hülsdünker J; Eskandarian Z; Dudek A; Schmitt-Graeff A; Wanders J; Jørgensen SF; Fevang B; Salzer U; Nieters A; Burns S; Grimbacher B
Clin Exp Immunol; 2016 Feb; 183(2):221-9. PubMed ID: 26437962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
